[ad_1]
(HealthDay) – During the first eight months of use of recombinant herpes zoster vaccine (RZV), 4,381 adverse events, including 3% of which were serious, have been reported, according to a study published in the US Centers for Disease Control of the United States. and prevention Weekly report on morbidity and mortality.
Elizabeth M. Hesse, MD, of the CDC in Atlanta, and her colleagues reviewed RZV virus safety surveillance data in the vaccine-related adverse event reporting system (VAERS).
The researchers found that VAERS had received a total of 4,381 reports of adverse events during the first eight months of use, when approximately 3.2 million doses of RZV were dispensed. Of these, 3% were clbadified as serious. Pyrexia, injection site pain, and erythema at the injection site were commonly reported signs and symptoms (23.6%, 22.5%, and 20.1%, respectively). There was no unexpected trend in reports of adverse or serious events.
"While initial safety data from RZV is rebaduring, the vaccine is still in its infancy, and the understanding of the safety of RZV will increase as use increases and new ones become available. data will be available from VAERS and the near real-time sequential monitoring of the Vaccine Safety Datalink CDC, "write the authors.
No new adverse events reported for DTaP vaccination
Summary / Full text
Copyright © 2019 HealthDay. All rights reserved.
Quote:
CDC examines the safety of recombinant herpes zoster vaccine (February 4, 2019)
recovered on February 4, 2019
of https://medicalxpress.com/news/2019-02-cdc-safety-recombinant-zoster-vaccine.html
This document is subject to copyright. Apart from any fair use for study or private research purposes, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link
